92
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Genome Wide Association Identifies Common Variants at the SERPINA6/SERPINA1 Locus Influencing Plasma Cortisol and Corticosteroid Binding Globulin

      research-article
      1 , 2 , 3 , 4 , 5 , 5 , 1 , 2 , 6 , 6 , 6 , 2 , 2 , 6 , 3 , 3 , 3 , 7 , 7 , 8 , 9 , 9 , 10 , 8 , 11 , 12 , 13 , 14 , 15 , 15 , 16 , 17 , 18 , 19 ,   19 , 20 , 19 , 20 , 21 , 21 , 22 , 23 , 21 , 24 , 25 , 26 , 27 , 28 , 24 , 28 , 29 , 29 , 29 , 30 , 30 , 31 , 32 , 31 , 33 , 34 , 34 , 34 , 6 , 1 , 1 , 3 , 1 , * , on behalf of the CORtisol NETwork (CORNET) Consortium
      PLoS Genetics
      Public Library of Science

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Variation in plasma levels of cortisol, an essential hormone in the stress response, is associated in population-based studies with cardio-metabolic, inflammatory and neuro-cognitive traits and diseases. Heritability of plasma cortisol is estimated at 30–60% but no common genetic contribution has been identified. The CORtisol NETwork (CORNET) consortium undertook genome wide association meta-analysis for plasma cortisol in 12,597 Caucasian participants, replicated in 2,795 participants. The results indicate that <1% of variance in plasma cortisol is accounted for by genetic variation in a single region of chromosome 14. This locus spans SERPINA6, encoding corticosteroid binding globulin (CBG, the major cortisol-binding protein in plasma), and SERPINA1, encoding α1-antitrypsin (which inhibits cleavage of the reactive centre loop that releases cortisol from CBG). Three partially independent signals were identified within the region, represented by common SNPs; detailed biochemical investigation in a nested sub-cohort showed all these SNPs were associated with variation in total cortisol binding activity in plasma, but some variants influenced total CBG concentrations while the top hit (rs12589136) influenced the immunoreactivity of the reactive centre loop of CBG. Exome chip and 1000 Genomes imputation analysis of this locus in the CROATIA-Korcula cohort identified missense mutations in SERPINA6 and SERPINA1 that did not account for the effects of common variants. These findings reveal a novel common genetic source of variation in binding of cortisol by CBG, and reinforce the key role of CBG in determining plasma cortisol levels. In turn this genetic variation may contribute to cortisol-associated degenerative diseases.

          Author Summary

          Cortisol is a steroid hormone from the adrenal glands that is essential in the response to stress. Most cortisol in blood is bound to corticosteroid binding globulin (CBG). Diseases causing cortisol deficiency (Addison's disease) or excess (Cushing's syndrome) are life-threatening. Variations in plasma cortisol have been associated with cardiovascular and psychiatric diseases and their risk factors. To dissect the genetic contribution to variation in plasma cortisol, we formed the CORtisol NETwork (CORNET) consortium and recruited collaborators with suitable samples from more than 15,000 people. The results reveal that the major genetic influence on plasma cortisol is mediated by variations in the binding capacity of CBG. This is determined by differences in the circulating concentrations of CBG and also in the immunoreactivity of its ‘reactive centre loop’, potentially influencing not only binding affinity for cortisol but also the stability of CBG and hence the tissue delivery of cortisol. These findings provide the first evidence for a common genetic effect on levels of this clinically important hormone, suggest that differences in CBG between individuals are biologically important, and pave the way for further research to dissect causality in the associations of plasma cortisol with common diseases.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?

          Associations between modifiable exposures and disease seen in observational epidemiology are sometimes confounded and thus misleading, despite our best efforts to improve the design and analysis of studies. Mendelian randomization-the random assortment of genes from parents to offspring that occurs during gamete formation and conception-provides one method for assessing the causal nature of some environmental exposures. The association between a disease and a polymorphism that mimics the biological link between a proposed exposure and disease is not generally susceptible to the reverse causation or confounding that may distort interpretations of conventional observational studies. Several examples where the phenotypic effects of polymorphisms are well documented provide encouraging evidence of the explanatory power of Mendelian randomization and are described. The limitations of the approach include confounding by polymorphisms in linkage disequilibrium with the polymorphism under study, that polymorphisms may have several phenotypic effects associated with disease, the lack of suitable polymorphisms for studying modifiable exposures of interest, and canalization-the buffering of the effects of genetic variation during development. Nevertheless, Mendelian randomization provides new opportunities to test causality and demonstrates how investment in the human genome project may contribute to understanding and preventing the adverse effects on human health of modifiable exposures.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Glucocorticoids and cardiovascular disease.

            Chronic excessive activation of glucocorticoid receptors induces obesity, insulin resistance, glucose intolerance, dyslipidaemia and hypertension. Subtle abnormalities of the hypothalamic-pituitary-adrenal axis and/or of tissue sensitivity to glucocorticoids are also associated with these cardiovascular risk factors in patients with the metabolic syndrome. Furthermore, glucocorticoids have direct effects on the heart and blood vessels, mediated by both glucocorticoid and mineralocorticoid receptors and modified by local metabolism of glucocorticoids by the 11beta-hydroxysteroid dehydrogenase enzymes. These effects influence vascular function, atherogenesis and vascular remodelling following intra-vascular injury or ischaemia. This article reviews the systemic and cardiovascular effects of glucocorticoids, and the evidence that glucocorticoids not only promote the incidence and progression of atherogenesis but also modify the recovery from occlusive vascular events and intravascular injury. The conclusion is that manipulation of glucocorticoid action within metabolic and cardiovascular tissues may provide novel therapeutic avenues to combat cardiovascular disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cortisol effects on body mass, blood pressure, and cholesterol in the general population.

              The effects of excess cortisol secretion on blood pressure and fat deposition are well documented, but the importance of this glucocorticoid in controlling these processes in normal individuals is less clear. We studied the relationship between cortisol excretion rate (tetrahydrocortisol [THF]+allo-THF+tetrahydrocortisone [THE]) and a range of important cardiovascular risk factors in 439 normal subjects (238 male) sampled from the North of Glasgow (Scotland) population. There were marked gender differences: female subjects were lighter and had lower blood pressures and cortisol levels, whereas HDL cholesterol was higher. The pattern of cortisol metabolism was also different; the index of 11beta-hydroxysteroid dehydrogenase activity (THF+allo-THF/THE) was lower and that of 5alpha-reductase (allo-THF/THF) was higher. There was a strong correlation of blood pressure (positive), cholesterol (positive), and HDL cholesterol (negative in women, positive in men) with age. Cortisol excretion rate did not correlate with blood pressure but correlated strongly with parameters of body habitus (body mass index and waist and hip measurements [positive]) and HDL cholesterol (negative). With multiple regression analysis, there remained a significant association of cortisol excretion rate with HDL cholesterol in men and women and with body mass index in men. These results suggest that glucocorticoids regulate key components of cardiovascular risk.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS Genet
                PLoS Genet
                plos
                plosgen
                PLoS Genetics
                Public Library of Science (San Francisco, USA )
                1553-7390
                1553-7404
                July 2014
                10 July 2014
                : 10
                : 7
                : e1004474
                Affiliations
                [1 ]University/BHF Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom
                [2 ]MRC Human Genetics Unit, Institute for Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom
                [3 ]Department of Epidemiology, Erasmus Medical Centre, Rotterdam, The Netherlands
                [4 ]Canterbury Health Laboratories, Christchurch, New Zealand
                [5 ]Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, Canada
                [6 ]Centre for Population Health Sciences, Institute for Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom
                [7 ]Institute of Behavioural Sciences, University of Helsinki, Helsinki, Finland
                [8 ]National Institute for Health and Welfare, Helsinki, Finland
                [9 ]Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
                [10 ]Department of Medical Genetics, University of Helsinki and University Central Hospital, Helsinki, Finland
                [11 ]Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland
                [12 ]Helsinki University Central Hospital, Unit of General Practice, Helsinki, Finland
                [13 ]Folkhalsan Research Centre, Helsinki, Finland
                [14 ]Vasa Central Hospital, Vasa, Finland
                [15 ]Institute of Health Sciences and Biocenter Oulu, University of Oulu, Oulu, Finland
                [16 ]Department of Children and Young People and Families, National Institute for Health and Welfare, Oulu, Finland
                [17 ]Department of Epidemiology and Biostatistics, MRC-HPA Centre for Environment and Health, Imperial College London, London, United Kingdom
                [18 ]Unit of Primary Care, Oulu University Hospital, Oulu, Finland
                [19 ]MRC Centre for Causal Analyses in Translational Epidemiology, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
                [20 ]School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
                [21 ]Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, Maryland, United States of America
                [22 ]Department of Psychiatry, VU University Medical Center/GGZ inGeest, Amsterdam, The Netherlands
                [23 ]Geriatric Unit, ASF, Florence, Italy
                [24 ]University of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, The Netherlands
                [25 ]University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands
                [26 ]Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, The Netherlands
                [27 ]University of Groningen, University Medical Center Groningen, Interdisciplinary Center for Psychiatric Epidemiology, Groningen, The Netherlands
                [28 ]University of Groningen, University Medical Center Groningen, Department of Internal Medicine, Groningen, The Netherlands
                [29 ]Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
                [30 ]Department of Medical Sciences, Uppsala University, Uppsala, Sweden
                [31 ]Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
                [32 ]School of Women's and Infant's Health, The University of Western Australia, Crawley, Australia
                [33 ]Department of Physiology, University of Toronto, Toronto, Ontario, Canada
                [34 ]Center for Bone and Arthritis Research, Institute of Medicin, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
                University of Michigan, United States of America
                Author notes

                The authors have declared that no competing interests exist.

                Conceived and designed the experiments: BRW HC AW HT. Performed the experiments: JLB CH ND JGL GLH LAH AA JH FPV JL JGE MK NJT TT PvdH AMa CML LNA JE JFP. Analyzed the data: JLB CH ND HT BRW. Contributed reagents/materials/analysis tools: JFW HC IR AW NH SHW AH AGU KR EK EW AP MRJ GDS SMR DME BSP YM SB LF JGMR SJLB NV RPFD AMo LL EI CEP SJL SGM DM CO MWJS RMR HT. Wrote the paper: JLB CH ND HT BRW.

                Article
                PGENETICS-D-13-03294
                10.1371/journal.pgen.1004474
                4091794
                25010111
                5af28d60-8404-40ed-9c80-e392168e0d58
                Copyright @ 2014

                This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

                History
                : 29 November 2013
                : 15 May 2014
                Page count
                Pages: 11
                Funding
                The CORtisol NETwork Consortium is funded by the Chief Scientist Office of the Scottish Government (grant CZB-4-733) and the British Heart Foundation (grant RG11/4/28734). The CROATIA-Vis, CROATIA-Korcula and CROATIA-Split studies were funded by grants from the Medical Research Council (UK), the Republic of Croatia Ministry of Science, Education and Sports research grants to IR (108-1080315-0302), and European Commission Framework 6 project EUROSPAN (Contract No. LSHG-CT-2006-018947). ORCADES was supported by the Chief Scientist Office of the Scottish Government, the Royal Society, the MRC Human Genetics Unit, Arthritis Research UK and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947). In the Rotterdam Study, the generation and management of genome-wide association study genotype data are supported by the Netherlands Organisation of Scientific Research Investments (number 175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-015) and the Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research project number 050-060-810. The Rotterdam Study is funded by Erasmus MC and Erasmus University, Rotterdam, the Netherlands Organization for the Health Research and Development, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (Directorate-General XII), and the Municipality of Rotterdam. HT was supported by the Vidi Grant of Netherlands Organization for the Health Research and Development (2009-017.106.370). ND was supported by the Netherlands Consortium for Healthy Ageing. The Helsinki Birth Cohort Study has been supported by grants from the Academy of Finland, the Finnish Diabetes Research Society, Folkhälsan Research Foundation, Novo Nordisk Foundation, Finska Läkaresällskapet, Signe and Ane Gyllenberg Foundation, University of Helsinki, European Science Foundation (EUROSTRESS), Ministry of Education, Ahokas Foundation, Emil Aaltonen Foundation, Juho Vainio Foundation, and Wellcome Trust (grant number WT089062). The Northern Finland Birth Cohort 1966 study is supported by the Academy of Finland [project grants 104781, 120315, 129418, Center of Excellence in Complex Disease Genetics and Public Health Challenges Research Program (SALVE)], University Hospital Oulu, Biocenter, University of Oulu, Finland (75617), the European Commission [EUROBLCS, Framework 5 award QLG1-CT-2000-01643], The National Heart, Lung and Blood Institute [5R01HL087679-02] through the SNP Typing for Association with Multiple Phenotypes from Existing Epidemiologic Data (STAMPEED) program [1RL1MH083268-01], The National Institute of Health/The National Institute of Mental Health [5R01MH63706:02], European Network of Genomic and Genetic Epidemiology (ENGAGE) project and grant agreement [HEALTH-F4-2007-201413], and the Medical Research Council, UK [G0500539, G0600705, PrevMetSyn/Public Health Challenges Research Program (SALVE)]. ALSPAC was funded by the UK Medical Research Council and the Wellcome Trust (Grant ref: 092731) and the University of Bristol. The InCHIANTI study has been supported by the Italian Ministry of Health and the U.S. National Institute on Aging. The PIVUS study was supported by Wellcome Trust Grants WT098017, WT064890, WT090532, Uppsala University, Uppsala University Hospital, the Swedish Research Council and the Swedish Heart-Lung Foundation. The PREVEND Study has been supported by the Dutch Kidney Foundation (Grant E.033), the Groningen University Medical Center (Beleidsruimte), Bristol Myers Squibb, Dade Behring, Ausam, Roche, Abbott, The Netherlands Organization of Scientific Research, The Dutch Heart Foundation, and the De Cock Foundation. The Edinburgh Type 2 Diabetes Study was funded by the UK Medical Research Council (G0500877). For the Raine Study, this work was supported by funding for the 17 year follow-up and genotyping provided by the National Health and Medical Research Council of Australia (353514, 572613, 403981) and the Canadian Institutes of Health Research (MOP82893). Core funding for the Raine Study is provided by the University of Western Australia (UWA), Raine Medical Research Foundation, the Telethon Institute for Child Health Research, UWA Faculty of Medicine, Dentistry and Health Sciences, the Women and Infants Research Foundation and Curtin University. The MrOS-Sweden study was supported by the Swedish Research Council, the Swedish Foundation for Strategic Research, European Commission Grant QLK4-CT-2002-02528, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar Söderber's Foundation, Petrus and Augusta Hedlunds Foundation, and the Novo Nordisk Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Medicine and Health Sciences
                Cardiology
                Endocrinology
                Epidemiology
                Mental Health and Psychiatry
                Metabolic Disorders

                Genetics
                Genetics

                Comments

                Comment on this article